Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
World Neurosurg ; 187: e839-e851, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38729520

RESUMEN

BACKGROUND: The head and neck cutaneous melanoma (HNCM) accounts for 20% of newly diagnosed melanoma. Research on prognostic models for their survival yet remains largely unexplored. This study employed a nomogram approach to develop and validate a predictive model for both overall survival (OS) and disease-specific survival (DSS) in patients with HNCM. METHODS: This study analyzed the HNCM patients diagnosed between 2004 and 2014 from Surveillance, Epidemiology, and End Results database. To identify independent prognostic factors for HNCM, we integrated results from univariate Cox regression analysis, random survival forests, and LASSO regression with cross-validation. A nomogram was designed and validated based on the identified characteristics to predict the 3-, 5-, and 8-year OS and DSS of patients with HNCM. RESULTS: Age, Stage, Ulceration, Thickness, Chemotherapy, lymph node metastasis, and Radiation were identified as independent prognostic factors. The nomogram achieved a satisfactory performance with C-indices of 0.824(DSS) and 0.757(OS) in the training cohort and 0.827(DSS) and 0.749(OS) in the validation cohort, respectively. The area under the curves for the OS at 3, 5, and 8 years were 0.789, 0.788, and 0.794 for the training cohort, and 0.778, 0.776, and 0.795 for the validation cohort, respectively. For DSS, the area under the curves at 3, 5, and 8 years were 0.859, 0.842, and 0.828 in the training cohort, and 0.864, 0.844, and 0.834 in the validation cohort, respectively. The calibration curve showed that there was a strong correlation between the observed outcomes and the predicted survival probability. CONCLUSIONS: This study established and validated predictive nomograms for HNCM patients with robust predictive performance.


Asunto(s)
Neoplasias de Cabeza y Cuello , Melanoma , Nomogramas , Programa de VERF , Neoplasias Cutáneas , Humanos , Melanoma/mortalidad , Melanoma/diagnóstico , Melanoma/terapia , Femenino , Neoplasias de Cabeza y Cuello/mortalidad , Neoplasias de Cabeza y Cuello/terapia , Neoplasias de Cabeza y Cuello/diagnóstico , Masculino , Neoplasias Cutáneas/mortalidad , Persona de Mediana Edad , Anciano , Pronóstico , Adulto , Anciano de 80 o más Años , Melanoma Cutáneo Maligno
2.
J Diabetes Investig ; 14(2): 339-343, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36412546

RESUMEN

AIMS/INTRODUCTION: In this study, we aimed to investigate the relationships between gamma-glutamyl transferase (GGT) and fasting blood glucose (FBG) during a 6-year follow-up study of participants, and to determine whether GGT is a risk factor for FBG. MATERIALS AND METHODS: A total of 1,369 individuals from the health examination survey in the urban area of Xuzhou, central China, were followed up for 6 years. The patients were divided into four groups based on their baseline GGT levels (in quartiles). The one-way analysis of variance (anova) method was used to compare the differences between the variables and baseline. The relationship between GGT and FBG levels was investigated using repeated measurements anova. RESULTS: The grouping of baseline GGT levels affected the changes in blood glucose during the 6-year follow-up study. In the GGT quartile subgroups, the annual mean increase in FBG levels showed a positive relationship with baseline GGT levels. This trend was even more aggregated in the highest baseline GGT group. Interactions among time course, baseline FBG and GGT groups in different participants together affected the change of FBG levels during the follow-up period. The repeated measures anova suggested that different baseline GGT groups were still significantly associated with increased FBG levels. GGT is a risk factor that affects FBG levels(P < 0.001). CONCLUSIONS: The annual mean increase in FBG levels showed a positive relationship with baseline GGT levels. Higher baseline GGT levels resulted in a faster annual mean increase in FBG. Thus, GGT can be used for the early detection of FBG-related disorders of glucose metabolism for clinical application.


Asunto(s)
Glucemia , gamma-Glutamiltransferasa , Humanos , Estudios de Seguimiento , Pueblos del Este de Asia , Biomarcadores , Factores de Riesgo , Ayuno
3.
J Diabetes Complications ; 35(4): 107855, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33558148

RESUMEN

The understanding of the genetic basis of type 2 diabetes mellitus (T2DM) has progressed rapidly, but the interactions among common genetic variants and metabolic risk factors have not been systematically investigated in studies with adequate statistical power. Therefore, we aimed to quantify the combined effects of genetic and metabolic environments on the risk of T2DM. Obesity is emerging as an independent risk factor for T2DM and arterial stiffness. Here, we examined the effect of the rs9356744 polymorphism in the body mass index (BMI) gene CDKAL1 on the risk of T2DM in East Asians and particularly assessed the interactions between this polymorphism and other metabolic risk factors. A total of 1975 subjects in whom the rs9356744 polymorphism had been detected in the CDKAL1 gene were enrolled in this study. The height, weight, blood pressure and relevant markers, including glucose, lipids, liver and renal function, of the participants were successfully measured. Pulse wave velocity (PWV) was measured using an automatic wave form analyzer. At baseline, we found a significant association between BMI and rs9356744 genotypes (CC, CT, TT) (P = 0.048). After adjusting for confounding factors, including sex, age and BMI, participants carrying the T allele of rs9356744 showed a lower incidence of T2DM. Further adjustment for blood pressure and lipids did not appreciably change the results (P = 0.019, 0.009, 0.015, respectively). We found significant interactions between the rs9356744 polymorphism and high-density lipoprotein (HDL), serum uric acid (SUA) and carotid-femoral pulse wave velocity (cf-PWV) in relation to T2DM incidence (P for interaction = 0.007, 0.002, 0.004, respectively), especially in the group with the lowest SUA level and the group with the highest HDL and cf-PWV levels (P for trend = 0.006, 0.008, 0.018, respectively). Furthermore, we found a significant interaction between the rs9356744 polymorphism and cf-PWV in relation to the level of 2-h plasma glucose in the oral glucose tolerance test (OGTT) (P for interaction = 0.0341). In summary, the T allele of rs9356744 was an independent protective factor for T2DM. There were significant interactions between rs9356744 and HDL, SUA, and cf-PWV in relation to T2DM risk.


Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Rigidez Vascular , ARNt Metiltransferasas/genética , Pueblo Asiatico/genética , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/genética , China/epidemiología , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/genética , Humanos , Lípidos , Análisis de la Onda del Pulso , Factores de Riesgo , Ácido Úrico , Rigidez Vascular/genética
4.
Medicine (Baltimore) ; 99(48): e23448, 2020 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-33235130

RESUMEN

This study aimed to detail the clinical outcomes of patients suffering from celiac arterial aneurysm (CAA) that underwent treatment via stent occlusion.This is a single-center, retrospective study. A total of 8 consecutive CAA patients were treated via stent occlusion from March 2014 to September 2018 at our hospital. Follow-up computed tomography was conducted after stenting at 1, 3, 6, and 12-month time points and every year thereafter. Both short- and long-term outcomes were assessed.In total, 8 stents were inserted into these 8 patients, with 2 being uncovered and 6 being covered stents. In 2 patients, stents were positioned in the celiac artery, while in the remaining 6 patients they were placed in the celiac and common hepatic arteries. The median operative duration was 66 minutes. No patients exhibited procedure-associated complications, and the median follow-up duration was 39 months (range: 18-72). Abdominal contrast-enhanced CT analyses of these patients exhibited stent and distal artery patency in 100% of patients, together with CAA obliteration. Visceral necrosis did not occur in any patients over the follow-up period.Stent occlusion can be safely and effectively used to treat CAA patients.


Asunto(s)
Aneurisma/cirugía , Arteria Celíaca/cirugía , Procedimientos Endovasculares , Stents , Adulto , Anciano , Aneurisma/diagnóstico por imagen , Arteria Celíaca/diagnóstico por imagen , Angiografía por Tomografía Computarizada , Medios de Contraste , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Grado de Desobstrucción Vascular
5.
J BUON ; 22(2): 725-729, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28730781

RESUMEN

PURPOSE: To determine the feasibility and safety of treating patients with advanced gastric cancer with laparoscopy. METHODS: We retrospectively analyzed 180 patients with advanced gastric carcinoma and divided them into either the laparoscopy group (96 cases) or the laparotomy group (84 cases). RESULTS: The number of lymph nodes dissected during surgery and the surgical time were similar in both groups. The incision length, total amount of bleeding during the operation, postoperative exhaust recovery time, and the length of hospital stay were significantly improved in the laparoscopy group when compared to the laparotomy group. The rate of postoperative complications was also significantly lower in the laparoscopy group. The levels of C-reactive protein (CRP) at 1, 7, and 10 days after surgery were significantly lower in the laparoscopy group. CONCLUSION: Overall, the laparoscopic radical operation for advanced gastric carcinoma demonstrated higher safety, shorter incision less bleeding, faster postoperative recovery, and lower rate of postoperative complications compared to the laparotomy group. Thus, this study has shown clear advantages for shifting to laparoscopy for the treatment of advanced gastric carcinoma.


Asunto(s)
Carcinoma/cirugía , Laparoscopía/efectos adversos , Laparoscopía/métodos , Neoplasias Gástricas/cirugía , Pérdida de Sangre Quirúrgica/prevención & control , Proteína C-Reactiva/metabolismo , Humanos , Laparotomía/efectos adversos , Laparotomía/métodos , Tiempo de Internación , Escisión del Ganglio Linfático/métodos , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/cirugía , Tempo Operativo , Complicaciones Posoperatorias/cirugía , Periodo Posoperatorio , Estudios Retrospectivos , Resultado del Tratamiento
6.
Int J Oncol ; 50(1): 15-22, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27909714

RESUMEN

Gastric cancer is the fourth most common type of cancer and the second cause of cancer­related mortalities worldwide despite the use of multimodal therapy. Cadherins are transmembrane glycoproteins that are involved in tumorigenesis. CDH17 has been found to be over­expressed in gastric cancer and its overexpression was associated with lymph node metastasis and tumor­node­metastasis stage of the patients, yet the exact role and molecular mechanism of CDH17 in gastric cancer have not been determined. Using a lentiviral system as a delivery mediator of RNA interference, we found that inhibition of CDH17 can lead to reduce proliferation and increase apoptosis of gastric cancer cell line MKN28 in vitro and significantly diminish their tumorigenicity in vivo. Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer.


Asunto(s)
Biomarcadores de Tumor/biosíntesis , Cadherinas/biosíntesis , Proliferación Celular/genética , Neoplasias Gástricas/genética , Animales , Apoptosis/genética , Biomarcadores de Tumor/genética , Cadherinas/antagonistas & inhibidores , Cadherinas/genética , Carcinogénesis/genética , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Humanos , Lentivirus/genética , Metástasis Linfática , Ratones , Interferencia de ARN , Neoplasias Gástricas/patología , Ensayos Antitumor por Modelo de Xenoinjerto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA